Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy
- PMID: 17440983
- DOI: 10.1002/cncr.22677
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy
Abstract
Background: The mammalian target of rapamycin (mTOR) pathway is up-regulated in many human cancers, and agents targeting the mTOR pathway are in various stages of clinical development. The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway in renal cell carcinoma (RCC).
Methods: Immunohistochemical analysis using antibodies against pAkt, PTEN, p27, and pS6 was performed on a tissue microarray constructed from paraffin-embedded specimens from 375 patients treated by nephrectomy for RCC. The expression was associated with pathological parameters and survival.
Results: The mTOR pathway was more significantly altered in clear-cell RCC, high-grade tumors, and tumors with poor prognostic features. PS6 and PTEN showed the strongest associations with pathological parameters. Survival tree analysis regarding expression of cytoplasmic pAkt, nuclear pAkt, PTEN, cytoplasmic p27, and pS6 identified staining percentages of 40%, 10%, 75%, 7%, and 70%, respectively, as ideal cutoff values for stratification, with corresponding P-values of .03, .001, .02, .005, and <.0001, respectively. Interestingly, high nuclear pAkt expression was associated with a favorable prognosis, whereas high cytoplasmic pAkt expression was associated with a poor prognosis. In multivariate Cox regression analysis, ECOG PS, T classification, N classification, M classification, cytoplasmic Akt, nuclear pAkt, PTEN, and pS6 were independent prognostic factors of DSS.
Conclusions: Components of the mTOR pathway are significantly associated with pathological features and survival. Not all RCC tumor types seem to be equally amenable to mTOR targeted therapy. PTEN, pAkt, p27, and pS6 may serve as surrogate parameters for patient selection and predicting prognosis. Patients with a highly activated mTOR pathway should benefit most from this therapy. External validation of our results is recommended.
(c) 2007 American Cancer Society.
Similar articles
-
Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.Urol Oncol. 2014 Jan;32(1):49.e15-21. doi: 10.1016/j.urolonc.2013.07.014. Epub 2013 Nov 13. Urol Oncol. 2014. PMID: 24239474
-
Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.J Surg Res. 2011 Jun 1;168(1):97-102. doi: 10.1016/j.jss.2009.06.025. Epub 2009 Jul 18. J Surg Res. 2011. PMID: 20036387
-
The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.Cancer. 2011 Jan 15;117(2):290-300. doi: 10.1002/cncr.25402. Epub 2010 Sep 9. Cancer. 2011. PMID: 20830770
-
mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.Expert Rev Mol Diagn. 2009 Apr;9(3):231-41. doi: 10.1586/erm.09.8. Expert Rev Mol Diagn. 2009. PMID: 19379082 Review.
-
Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway.J Neuropathol Exp Neurol. 2005 Apr;64(4):341-9. doi: 10.1093/jnen/64.4.341. J Neuropathol Exp Neurol. 2005. PMID: 15835270 Review.
Cited by
-
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.J Clin Invest. 2016 Sep 1;126(9):3526-40. doi: 10.1172/JCI86120. Epub 2016 Aug 2. J Clin Invest. 2016. PMID: 27482884 Free PMC article.
-
pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation.Int J Nanomedicine. 2024 Sep 23;19:9821-9841. doi: 10.2147/IJN.S469913. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39345910 Free PMC article.
-
Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma.PLoS One. 2015 Feb 25;10(2):e114250. doi: 10.1371/journal.pone.0114250. eCollection 2015. PLoS One. 2015. PMID: 25714556 Free PMC article.
-
Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.BMC Syst Biol. 2010 Apr 27;4:51. doi: 10.1186/1752-0509-4-51. BMC Syst Biol. 2010. PMID: 20420713 Free PMC article.
-
Common corruption of the mTOR signaling network in human tumors.Oncogene. 2008 Dec;27 Suppl 2(0 2):S43-51. doi: 10.1038/onc.2009.352. Oncogene. 2008. PMID: 19956179 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous